Cellectis (CLLS) Stock Price, News & Analysis

Company Overview

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies. Its pipeline includes multiple CAR‐T candidates, such as those targeting CD19 and CD22 antigens for B‐cell malignancies and other programs addressing acute myeloid leukemia. Cellectis advances these investigational therapies through preclinical research and early‐ to mid‐stage clinical trials, often in partnership with leading pharmaceutical firms to enhance development and commercialization capabilities.

Cellectis operates research and process development laboratories as well as GMP manufacturing facilities across Europe and North America. Clinical trials are conducted in premier cancer centers in the United States and Europe, reflecting the company’s global reach. Strategic collaborations and licensing agreements support the expansion of its gene‐edited therapies into new indications and geographic markets, with an emphasis on scalable production and regulatory readiness.

Under the leadership of founder and Chief Executive Officer Dr. André Choulika, Cellectis has established itself as a pioneer in TALEN‐based genome editing. The management team combines scientific and commercial expertise to drive innovation, with a focus on delivering next‐generation allogeneic CAR‐T therapies to patients worldwide.

Key Stats

• Today's Range: $4.11 to $4.59
• 50-Day Range: $2.51 to $4.30
• 52-Week Range: $1.10 to $4.59
• Volume: 554,524 shs
• Average Volume: 151,754 shs
• Market Capitalization: $212.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Cellectis Stock Analysis - MarketRank™

Cellectis scored higher than 8% of companies evaluated by MarketBeat, and ranked 867th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cellectis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Downside Risk

Cellectis has a consensus price target of $4.00, representing about 7.0% downside from its current price of $4.30.

Amount of Analyst Coverage

Cellectis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cellectis are expected to decrease in the coming year, from ($0.46) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellectis is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellectis is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cellectis has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Cellectis has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectis has recently increased by 22.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellectis does not currently pay a dividend.

Dividend Growth

Cellectis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Cellectis has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectis has recently increased by 22.66%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Cellectis this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for CLLS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cellectis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellectis insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CLLS Stock Analysis - Frequently Asked Questions

How have CLLS shares performed this year?

Cellectis' stock was trading at $1.80 at the beginning of 2025. Since then, CLLS stock has increased by 138.9% and is now trading at $4.30.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) posted its quarterly earnings results on Monday, August, 4th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.09. The biotechnology company earned $18.19 million during the quarter, compared to analysts' expectations of $10.07 million. Cellectis had a negative trailing twelve-month return on equity of 68.05% and a negative net margin of 100.69%.
Read the conference call transcript.

When did Cellectis IPO?

Cellectis (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

How do I buy shares of Cellectis?

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLLS
• CIK: 1627281
• Web: www.cellectis.com
• Phone: (318) 169-1600
• Fax: 33-1-81-69-16-06
• Employees: 290
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cellectis: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: -6.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.76 million
• Net Margins: -100.69%
• Pretax Margin: -71.84%
• Return on Equity: -68.05%
• Return on Assets: -21.53%

Debt

• Debt-to-Equity Ratio: 0.58
• Current Ratio: 1.38
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: $49.22 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.36 per share
• Price / Book: 1.82

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: $196.21 million
• Optionable: Optionable
• Beta: 3.10